Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-08-06

Clinical Trial Update: An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update for lanabecestat in early Alzheimer's disease shows the study conduct with termination and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • lanabecestat (lanabecestat)

Snippet

Sponsor: AstraZeneca | Conditions: Alzheimer´s Disease | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2019-08-06